Adults 18 to 55, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Oocyst PrevalencePrimary· Feeding assays were performed on Day 1 and Day 2; Oocyst prevalence in surviving mosquitoes was assessed 9 days after feeding (Days 9 and 10).
Participants underwent feeding assays on two days, 24 hours apart (day 1 and Day 2). After feeding, mosquitoes were maintained in locked environmental chambers for 9 days to allow oocyst development.
An oocyst is a structure that develops on the outer wall of the infected mosquito's stomach that contains developing sporozoites.
Nine days after feeding mosquito midguts were dissected, stained with 1% mercurochrome and examined by optical microscopy. The number of oocysts in each midgut were recorded.
Oocyst prevalence is defined as the percentage of mosquitoes in a cup with at least one oocy
Day 1 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
5.2
± 7.8
Direct Membrane Feeding Assay
6.3
± 16.2
Day 2 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
2.3
± 4.9
Direct Membrane Feeding Assay
2.2
± 4.4
Oocyst DensitySecondary· Feeding assays were performed on Day 1 and Day 2; Oocyst density in surviving mosquitos was assessed 9 days after feeding (Days 9 and 10).
Participants underwent feeding assays on two days, 24 hours apart (Day 1 and Day 2). After feeding, mosquitoes were maintained in locked environmental chambers for 9 days to allow oocyst development.
An oocyst is a structure that develops on the outer wall of the infected mosquito's stomach that contains developing sporozoites.
Nine days after feeding mosquito midguts were dissected, stained with 1% mercurochrome and examined by optical microscopy. The number of oocysts in each midgut were recorded.
Oocyst density is defined as the mean number of oocysts detected in infected mosquitoes that
Day 1 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
1.1
± 1.8
Direct Membrane Feeding Assay
1.6
± 4.1
Day 2 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
0.4
± 0.8
Direct Membrane Feeding Assay
0.4
± 0.8
Sporozoite PrevalenceSecondary· Feeding assays were performed on Day 1 and Day 2; Sporozoite prevalence in surviving mosquitoes was assessed 14 days after feeding (Days 14 and 15).
Participants underwent feeding assays on two days, 24 hours apart (day 1 and Day 2). After feeding, mosquitoes were maintained in locked environmental chambers for 14 days to allow sporozoite development.
Sporozoites are the forms of the plasmodium that are liberated from the oocysts in the mosquito, accumulate in the salivary glands of the mosquito, and are transferred to humans when the mosquito feeds.
Fourteen days after feeding, salivary glands were dissected from live mosquitoes submerged in phosphate-buffered saline (PBS) in order to visualize motile sporozoites by microscopy. Sporozoi
Day 1 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
5.1
± 8.4
Direct Membrane Feeding Assay
4.5
± 8.0
Day 2 Feeding Assay
Group
Value
95% CI
Direct Skin Feeding Assay
1.8
± 4.8
Direct Membrane Feeding Assay
2.0
± 5.7
Adverse events — posted to ClinicalTrials.gov
Time frame: 2 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The proposed trial design has been developed to assess the consistency and reproducibility of two consecutive direct skin feeding assays (DSFA) at 24-hour interval.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
· recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
· Phase 2
· recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI
· Phase 1
· active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants
· Phase 1
· recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha
· Phase 1
· recruiting
Other PATH trials
Trials by the same sponsor.
NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
· Phase 2
· recruiting
NCT06129916 — Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PATH
Last refreshed: 29 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04666350.